CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：The Potential of Induced Pluripotent Stem Cells to Advance the Treatment of Pancreatic Ductal Adenocarcinoma.
The Potential of Induced Pluripotent Stem Cells to Advance the Treatment of Pancreatic Ductal Adenocarcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
胰腺导管腺癌（PDAC）的治疗进展，包括新辅助放化疗、化疗和免疫治疗，对患者的总生存期影响甚微。普遍缺乏免疫原性特征以及复杂的肿瘤微环境（TME）可能是PDAC治疗耐药的罪魁祸首。应探索诱导多能干细胞（iPSCs）作为推进PDAC治疗选择的手段，通过提供代表性的胰腺癌发展体外模型。此外，iPSCs可用于定制细胞免疫疗法，或在疫苗接种背景下作为肿瘤相关抗原的来源。
Advances in the treatment of pancreatic ductal adenocarcinoma (PDAC) using neoadjuvant chemoradiotherapy, chemotherapy, and immunotherapy have had minimal impact on the overall survival of patients. A general lack of immunogenic features and a complex tumor microenvironment (TME) are likely culprits for therapy refractoriness in PDAC. Induced pluripotent stem cells (iPSCs) should be explored as a means to advance the treatment options for PDAC, by providing representative in vitro models of pancreatic cancer development.
In addition, iPSCs could be used for tailor-made cellular immunotherapies or as a source of tumor-associated antigens in the context of vaccination.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
